Several randomized phase III trials1–8 demonstrated a significant survival benefit of EGFR-tyrosine kinase inhibitors (TKIs) over platinum-chemotherapy for naïve patients with advanced non-small cell lung cancer (NSCLC) carrying exon 19 deletion or exon 21 L858R point mutation. Here, EGFR is linked to non-small cell lung carcinoma.